CoChat
Sign Up
Cited by 455

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters

Lemonnier, François, Couronné, Lucile, Parrens, Marie, Jaïs, Jean-Philippe, Travert, Marion, Lamant, Laurence, Tournillac, Olivier, Rousset, Therese, Fabiani, Bettina, Cairns, Rob A., Mak, Tak, Bastard, Christian, Bernard, Olivier A., de Leval, Laurence, Gaulard, Philippe·2012·Blood
DOI 10.1182/blood-2012-02-408542
Open this paper in CoChat — free account

Abstract

Inactivating mutations of the Ten-Eleven Translocation 2 (TET2) gene were first identified in myeloid malignancies and more recently in peripheral T-cell lymphomas (PTCLs). In the present study, we investigated the presence of TET2 coding sequence mutations and their clinical relevance in a large cohort of 190 PTCL patients. TET2 mutations were identified in 40 of 86 (47%) cases of angioimmunoblastic T-cell lymphoma (AITL) and in 22 of 58 (38%) cases of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), but were absent in all other PTCL entities, with the exception of 2 of 10 cases of enteropathy-associated T-cell lymphoma. Among PTCL-NOS, a heterogeneous group of lymphoma-comprising cases likely to derive from Th follicular (TFH) cells similarly to AITL, TET2 mutations were more frequent when PTCL-NOS expressed TFH markers and/or had features reminiscent of AITL (58% vs 24%, P = .01). In the AITL and PTCL-NOS subgroups, TET2 mutations were associated with advanced-stage disease, thrombocytopenia, high International Prognostic Index scores, and a shorter progression-free survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2012-02-408542

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 19

  1. Abdel-Wahab, 2009, Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies., Blood, 114, 144, 10.1182/blood-2009-03-210039 · DOI · Paper page
  2. Tahiliani, 2009, Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1., Science, 324, 930, 10.1126/science.1170116 · DOI · Paper page
  3. Cimmino, 2011, TET family proteins and their role in stem cell differentiation and transformation., Cell Stem Cell, 9, 193, 10.1016/j.stem.2011.08.007 · DOI
  4. Quivoron, 2011, TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis., Cancer Cell, 20, 25, 10.1016/j.ccr.2011.06.003 · DOI · Paper page
  5. Li, 2011, Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies., Blood, 118, 4509, 10.1182/blood-2010-12-325241 · DOI · Paper page
  6. Couronné, 2012, TET2 and DNMT3A mutations in human T-cell lymphoma., N Engl J Med, 366, 95, 10.1056/NEJMc1111708 · DOI · Paper page
  7. Vose, 2008, International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes., J Clin Oncol, 26, 4124, 10.1200/JCO.2008.16.4558 · DOI
  8. Swerdlow, 2008, International Agency for Research on Cancer.
  9. Dupuis, 2006, Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells., Am J Surg Pathol, 30, 490, 10.1097/00000478-200604000-00009 · DOI
  10. de Leval, 2007, The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells., Blood, 109, 4952, 10.1182/blood-2006-10-055145 · DOI
  11. Piccaluga, 2007, Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation., Cancer Res, 67, 10703, 10.1158/0008-5472.CAN-07-1708 · DOI
  12. de Leval, 2008, Pathobiology and molecular profiling of peripheral T-cell lymphomas., Hematology Am Soc Hematol Educ Program, 2008, 272, 10.1182/asheducation.V2008.1.272.0010272 · DOI
  13. Rodríguez-Pinilla, 2008, Peripheral T-cell lymphoma with follicular T-cell markers., Am J Surg Pathol, 32, 1787, 10.1097/PAS.0b013e31817f123e · DOI
  14. Iqbal, 2010, Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma., Blood, 115, 1026, 10.1182/blood-2009-06-227579 · DOI
  15. Gallamini, 2004, Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study., Blood, 103, 2474, 10.1182/blood-2003-09-3080 · DOI
  16. Cairns, 2012, IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma., Blood, 119, 1901, 10.1182/blood-2011-11-391748 · DOI
  17. Pasqualucci, 2011, Inactivating mutations of acetyltransferase genes in B-cell lymphoma., Nature, 471, 189, 10.1038/nature09730 · DOI
  18. Morin, 2010, Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin., Nat Genet, 42, 181, 10.1038/ng.518 · DOI · Paper page
  19. Mourad, 2008, Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials., Blood, 111, 4463, 10.1182/blood-2007-08-105759 · DOI

Cited by

See all 455

Metadata

Authors
Lemonnier, F., Couronné, L., Parrens, M., Jaïs, J.-P., Travert, M., Lamant, L., Tournillac, O., Rousset, T., Fabiani, B., Cairns, R. A., Mak, T., Bastard, C., Bernard, O. A., de Leval, L., & Gaulard, P.
Affiliations
  • Inserm U955, Créteil, France;
  • Inserm U985, Institut Gustave Roussy; Université Paris, Villejuif, France;
  • Département de Pathologie, Hôpital Pessac, Bordeaux, France;
  • Département de Statistiques. Hôpital Necker, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris, France;
  • Département de Pathologie, Hôpital Purpan, Toulouse, France;
  • Service de Thérapie Cellulaire et d'Hématologie Clinique Adulte, Université d'Auvergne, Inserm CIC-501, Centre Hospitalier Universitaire Clermont-Ferrand Hôpital Estaing, Clermont-Ferrand, France;
  • Département d'Anatomie Pathologique, Centre Hospitalier Universitaire Gui de Chauliac, Montpellier, France;
  • Département d'Anatomie Pathologique, Hôpital Saint-Antoine, AP-HP, Paris, France;
  • Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital, University Health Network, Toronto, ON;
  • Inserm U918, Université de Rouen, Centre Henri Becquerel, Rouen, France;
  • Institut de Pathologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; and
Venue
Blood
Publisher
American Society of Hematology
Published
2012-08-16
Volume
120
Issue
7
Pages
1466-1469
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2012-02-408542
Cited by
455
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. https://app.cochat.ai/papers/10.1182/blood-2012-02-408542
The paper
Lemonnier, F., Couronné, L., Parrens, M., Jaïs, J.-P., Travert, M., Lamant, L., Tournillac, O., Rousset, T., Fabiani, B., Cairns, R. A., Mak, T., Bastard, C., Bernard, O. A., de Leval, L., & Gaulard, P. (2012). Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. https://doi.org/10.1182/blood-2012-02-408542